Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

207
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
207
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

220
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
220
Allergic Drug Reactions01:27

Allergic Drug Reactions

1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

208
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
208
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

753
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
753
Autoimmune Disorders01:29

Autoimmune Disorders

2.4K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
2.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patch test sensitization and permanent tattoos: epidemiological data from two referral centers.

European annals of allergy and clinical immunology·2026
Same author

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

Predictors of early treatment response to antihistamines and omalizumab in chronic spontaneous urticaria.

Frontiers in allergy·2026
Same author

Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Hidradenitis suppurativa with and without draining tunnels: A real-world study characterizing differences in treatment and disease burden.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Related Experiment Video

Updated: Apr 30, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K

Drug-induced lupus erythematosus.

A V Marzano1, S Tavecchio, C Menicanti

  • 1Operative Unit of Dermatology Department of Pathophysiology and Transplantation University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy - angelovalerio.marzano@policlinico.mi.it.

Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|May 14, 2014
PubMed
Summary

Drug-induced lupus erythematosus (DI-LE) mimics idiopathic lupus but resolves after drug withdrawal. DI-SCLE, the most common form, presents with widespread lesions and specific rashes, distinguishing it from other lupus types.

More Related Videos

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.7K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K

Related Experiment Videos

Last Updated: Apr 30, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

17.7K
Skin Biopsy for Diagnosing Discoid Lupus Erythematosus
05:44

Skin Biopsy for Diagnosing Discoid Lupus Erythematosus

Published on: June 10, 2025

1.7K
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
09:43

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

2.6K

Area of Science:

  • Dermatology
  • Immunology
  • Rheumatology

Background:

  • Drug-induced lupus erythematosus (DI-LE) shares clinical and serological features with idiopathic lupus.
  • DI-LE is categorized into systemic, subacute cutaneous (SCLE), chronic cutaneous (CCLE), and tumidus forms.
  • DI-SCLE is the predominant subtype of drug-induced cutaneous lupus.

Purpose of the Study:

  • To investigate the distinct clinical features of drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) compared to its idiopathic counterpart.
  • To identify diagnostic hallmarks for DI-SCLE.

Main Methods:

  • Comparative analysis of clinical manifestations and immunopathological findings in DI-LE and idiopathic lupus.
  • Review of histopathological data for DI-SCLE and other DI-LE variants.

Main Results:

  • DI-SCLE frequently presents with widespread annular-polycyclic lesions, often involving the lower legs, unlike idiopathic SCLE.
  • Malar rash, bullous, erythema multiforme-like, and vasculitic manifestations are characteristic of DI-SCLE.
  • Histopathology, including lichenoid interface dermatitis and tissue eosinophilia, is not a reliable differentiator for DI-SCLE.

Conclusions:

  • DI-SCLE exhibits distinct clinical features, notably malar rash and specific cutaneous manifestations, differentiating it from idiopathic SCLE.
  • Histological findings are not diagnostic for DI-SCLE.
  • Management of DI-LE primarily involves drug cessation, with immunomodulatory agents reserved for refractory cases.